PE20240817A1 - Mutantes de proteina f de rsv - Google Patents
Mutantes de proteina f de rsvInfo
- Publication number
- PE20240817A1 PE20240817A1 PE2023001148A PE2023001148A PE20240817A1 PE 20240817 A1 PE20240817 A1 PE 20240817A1 PE 2023001148 A PE2023001148 A PE 2023001148A PE 2023001148 A PE2023001148 A PE 2023001148A PE 20240817 A1 PE20240817 A1 PE 20240817A1
- Authority
- PE
- Peru
- Prior art keywords
- protein
- rsv
- mutant
- polypeptide
- subtype
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 241000701533 Escherichia virus T4 Species 0.000 abstract 1
- 101710189104 Fibritin Proteins 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invencion se refiere a mutantes de una proteina F de RSV de tipo silvestre y del subtipo A o B, los cuales comprenden un polipeptido F1 y F2 y mutaciones de aminoacidos introducidas relativas a la proteina F de RSV de tipo silvestre, por ejemplo, un par de mutaciones de cisteina que consiste en: 103C y 148C. Asimismo, las posiciones de los aminoacidos de esta proteina estan numeradas de acuerdo a la SEQ ID NO: 1. Tambien, refiere a los usos de moleculas de acido nucleico y vectores que codifican a los presentes mutantes y composiciones farmaceuticas, que comprenden un primer y segundo mutante, en donde el extremo C-terminal del polipeptido F1 del primer mutante de la proteina F del RSV de subtipo A y el extremo C-terminal del polipeptido F1 del segundo mutante de la proteina F del RSV de subtipo B, esta cada uno enlazado a un dominio plegado de fibritina del fago T4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562387270P | 2015-12-23 | 2015-12-23 | |
US201662421184P | 2016-11-11 | 2016-11-11 | |
PCT/IB2016/057502 WO2017109629A1 (en) | 2015-12-23 | 2016-12-09 | Rsv f protein mutants |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240817A1 true PE20240817A1 (es) | 2024-04-18 |
Family
ID=57590746
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018001128A PE20181354A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
PE2023001147A PE20232039A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
PE2023001148A PE20240817A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018001128A PE20181354A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
PE2023001147A PE20232039A1 (es) | 2015-12-23 | 2016-12-09 | Mutantes de proteina f de rsv |
Country Status (18)
Country | Link |
---|---|
US (5) | US9950058B2 (es) |
EP (1) | EP3393512A1 (es) |
JP (4) | JP6817307B2 (es) |
KR (3) | KR20230035429A (es) |
CN (1) | CN108738312A (es) |
AU (4) | AU2016379097C1 (es) |
BR (1) | BR112018010805A2 (es) |
CA (2) | CA3217696A1 (es) |
CO (1) | CO2018006301A2 (es) |
IL (2) | IL311990A (es) |
MX (2) | MX2018007622A (es) |
PE (3) | PE20181354A1 (es) |
PH (1) | PH12018501355A1 (es) |
RU (1) | RU2723039C2 (es) |
SA (1) | SA518391839B1 (es) |
SG (2) | SG11201804148TA (es) |
TW (4) | TWI707866B (es) |
WO (1) | WO2017109629A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6685903B2 (ja) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたrsv融合前fタンパク質 |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
RU2019130167A (ru) | 2017-04-04 | 2021-05-05 | Юниверсити Оф Вашингтон | Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение |
EP3664836A4 (en) | 2017-08-07 | 2021-05-19 | Calder Biosciences Inc. | PRE-FUSION RSV PRE-FUSION STABILIZED IN TERMS OF CONFORMITY |
WO2019147749A2 (en) * | 2018-01-29 | 2019-08-01 | Merck Sharp & Dohme Corp. | Stabilized rsv f proteins and uses thereof |
EP3758747A1 (en) | 2018-02-28 | 2021-01-06 | University of Washington | Self-asssembling nanostructure vaccines |
MX2021001479A (es) | 2018-08-07 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Novedosos procesos y vacunas. |
JOP20210106A1 (ar) * | 2018-11-13 | 2023-01-30 | Janssen Vaccines And Prevention B V | بروتينات rsv f سابقة الاندماج مستقرة |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN110054668B (zh) * | 2019-04-25 | 2021-09-10 | 北京交通大学 | 一种呼吸道合胞病毒融合前f蛋白及其应用 |
US20230201334A1 (en) | 2019-07-24 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
CN114502572A (zh) | 2019-09-04 | 2022-05-13 | 华盛顿大学 | 展示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途 |
WO2021132379A1 (ja) * | 2019-12-23 | 2021-07-01 | 田辺三菱製薬株式会社 | 変異型rsv fタンパク質及びその利用 |
TWI810589B (zh) * | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
CN112899214B (zh) * | 2020-07-07 | 2023-08-04 | 湖南师范大学 | 废弃鱼鳞在制备各向异性基底中的应用 |
JP2022023813A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産されたrsvタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良 |
JP2022023814A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産された三量体型のrsvタンパク質の精製方法 |
CN112226444B (zh) * | 2020-08-25 | 2022-11-04 | 北京交通大学 | 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品 |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
CN114685676B (zh) * | 2020-12-28 | 2024-02-13 | 兰州生物制品研究所有限责任公司 | 一种重组蛋白及其表达方法、纯化方法及用途 |
US20240228548A9 (en) * | 2021-02-19 | 2024-07-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
WO2022234405A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
CN117715923A (zh) * | 2022-04-29 | 2024-03-15 | 北京新合睿恩生物医疗科技有限公司 | Rsv f蛋白突变体及其应用 |
WO2024041773A1 (en) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Rsv-f proteins |
CN116003536A (zh) * | 2022-09-23 | 2023-04-25 | 暨南大学 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024078597A1 (en) * | 2022-10-13 | 2024-04-18 | Rvac Medicines (Us) , Inc. | Rsv f protein variants and uses thereof |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
WO2024093554A1 (zh) * | 2022-11-04 | 2024-05-10 | 北京康乐卫士生物技术股份有限公司 | 针对rsv的重组亚单位疫苗及其应用 |
CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
WO2024127181A1 (en) | 2022-12-11 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
CN117487823A (zh) * | 2023-09-28 | 2024-02-02 | 怡道生物科技(苏州)有限公司 | 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用 |
CN117304278B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117304279B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117304280B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117567652B (zh) * | 2024-01-19 | 2024-05-14 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原 |
CN117586359A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽 |
CN117645655B (zh) * | 2024-01-26 | 2024-05-24 | 普大生物科技(泰州)有限公司 | 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法 |
CN117777251B (zh) * | 2024-02-27 | 2024-06-04 | 普大生物科技(泰州)有限公司 | 一种rsv纳米颗粒疫苗及其制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
WO2008114149A2 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
WO2008154456A2 (en) | 2007-06-06 | 2008-12-18 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
SG188813A1 (en) * | 2007-12-24 | 2013-04-30 | Id Biomedical Corp Quebec | Recombinant rsv antigens |
CN102131830A (zh) | 2008-07-18 | 2011-07-20 | 魁北克益得生物医学公司 | 嵌合呼吸道合胞病毒多肽抗原 |
US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
AU2009333484B2 (en) | 2008-12-09 | 2014-12-11 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
KR20120093811A (ko) * | 2009-06-24 | 2012-08-23 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 백신 |
AU2010264688A1 (en) * | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
HRP20220756T1 (hr) | 2009-07-15 | 2022-09-02 | Glaxosmithkline Biologicals S.A. | Proteinski pripravci rsv f i postupci za izradu istih |
NZ599148A (en) | 2009-10-06 | 2014-08-29 | Medimmune Ltd | Rsv-specific binding molecule |
WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
EP4159232A1 (en) | 2011-01-26 | 2023-04-05 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
RS56748B1 (sr) | 2011-05-13 | 2018-03-30 | Glaxosmithkline Biologicals Sa | Pre-fuzioni rsv f antigeni |
ES2395677B1 (es) | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
CA2849471A1 (en) | 2011-09-30 | 2013-04-04 | Novavax, Inc. | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
AU2013237424B2 (en) | 2012-03-22 | 2017-07-06 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
EP2922570A1 (en) | 2012-11-20 | 2015-09-30 | GlaxoSmithKline Biologicals SA | Rsv f prefusion trimers |
RU2761631C2 (ru) * | 2013-03-13 | 2021-12-13 | Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Белки rsv в предшествующей слиянию конформации и их применение |
US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
TR201902513T4 (tr) | 2013-04-25 | 2019-03-21 | Janssen Vaccines & Prevention Bv | Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri. |
MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
JP6685903B2 (ja) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたrsv融合前fタンパク質 |
US20150166610A1 (en) * | 2013-10-14 | 2015-06-18 | Glaxosmithkline Biologicals, S.A. | Recombinant rsv antigens |
EP2974739A1 (en) * | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
CN108348593B (zh) * | 2015-08-31 | 2022-08-16 | 泰克诺瓦克斯股份有限公司 | 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗 |
US10496141B2 (en) | 2016-03-17 | 2019-12-03 | Qualcomm Incorporated | System and method for intelligent thermal management in a system on a chip having a heterogeneous cluster architecture |
-
2016
- 2016-12-09 CN CN201680075615.8A patent/CN108738312A/zh active Pending
- 2016-12-09 JP JP2018532448A patent/JP6817307B2/ja active Active
- 2016-12-09 AU AU2016379097A patent/AU2016379097C1/en active Active
- 2016-12-09 PE PE2018001128A patent/PE20181354A1/es unknown
- 2016-12-09 KR KR1020237006668A patent/KR20230035429A/ko not_active Application Discontinuation
- 2016-12-09 MX MX2018007622A patent/MX2018007622A/es unknown
- 2016-12-09 PE PE2023001147A patent/PE20232039A1/es unknown
- 2016-12-09 SG SG11201804148TA patent/SG11201804148TA/en unknown
- 2016-12-09 KR KR1020207020668A patent/KR102505354B1/ko active IP Right Grant
- 2016-12-09 IL IL311990A patent/IL311990A/en unknown
- 2016-12-09 IL IL260203A patent/IL260203B1/en unknown
- 2016-12-09 BR BR112018010805-7A patent/BR112018010805A2/pt active Search and Examination
- 2016-12-09 EP EP16816405.1A patent/EP3393512A1/en active Pending
- 2016-12-09 RU RU2018122823A patent/RU2723039C2/ru active
- 2016-12-09 WO PCT/IB2016/057502 patent/WO2017109629A1/en active Application Filing
- 2016-12-09 SG SG10202001389PA patent/SG10202001389PA/en unknown
- 2016-12-09 PE PE2023001148A patent/PE20240817A1/es unknown
- 2016-12-09 KR KR1020187017606A patent/KR102136678B1/ko active IP Right Grant
- 2016-12-19 CA CA3217696A patent/CA3217696A1/en active Pending
- 2016-12-19 CA CA2952131A patent/CA2952131C/en active Active
- 2016-12-20 US US15/385,611 patent/US9950058B2/en active Active
- 2016-12-22 TW TW107131547A patent/TWI707866B/zh active
- 2016-12-22 TW TW105142706A patent/TWI656130B/zh active
- 2016-12-22 TW TW111102562A patent/TWI838685B/zh active
- 2016-12-22 TW TW109132170A patent/TWI756828B/zh active
-
2018
- 2018-02-14 US US15/896,871 patent/US10238732B2/en active Active
- 2018-06-18 CO CONC2018/0006301A patent/CO2018006301A2/es unknown
- 2018-06-20 SA SA518391839A patent/SA518391839B1/ar unknown
- 2018-06-20 MX MX2021007070A patent/MX2021007070A/es unknown
- 2018-06-22 PH PH12018501355A patent/PH12018501355A1/en unknown
-
2019
- 2019-01-08 US US16/242,799 patent/US10821171B2/en active Active
- 2019-07-31 AU AU2019210579A patent/AU2019210579B2/en active Active
-
2020
- 2020-10-01 US US17/060,944 patent/US20210023200A1/en not_active Abandoned
- 2020-12-24 JP JP2020214835A patent/JP7193522B2/ja active Active
-
2021
- 2021-04-23 AU AU2021202522A patent/AU2021202522C1/en active Active
-
2022
- 2022-09-28 JP JP2022154365A patent/JP7212198B2/ja active Active
- 2022-11-17 JP JP2022184277A patent/JP2023015335A/ja active Pending
-
2023
- 2023-03-29 US US18/192,352 patent/US20230218738A1/en active Pending
- 2023-08-09 AU AU2023214269A patent/AU2023214269A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20240817A1 (es) | Mutantes de proteina f de rsv | |
CL2019001000A1 (es) | Proteínas de fusión fc heterodiméricas il15/il15ralfa | |
CO2018012096A2 (es) | Proteínas de fusión gdf15 y usos de estas | |
EA202090090A1 (ru) | Включение неприродных нуклеотидов и способы с ними | |
CO2018003863A2 (es) | Anticuerpos anti-vegf | |
CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
BR112017007816A2 (pt) | composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas | |
PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
PH12019500209A1 (en) | Methods and compositions for gene expression in plants | |
EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
EA201491051A1 (ru) | Вакцины против вируса гриппа и их применения | |
BR112017015833A2 (pt) | compostos anti-senescência e usos dos mesmos | |
EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
MX371033B (es) | Productos farmacéuticos mejorados de péptido para resistencia a la insulina. | |
MX371403B (es) | Moleculas de andamiaje a base de fibronectina estabilizada. | |
CO6210831A2 (es) | Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal | |
WO2016130628A8 (en) | Griffithsin mutants | |
EA202091769A1 (ru) | Вакцины против вируса гриппа и пути их применения | |
EA201891141A1 (ru) | Новые антиангиогенные слитые полипептиды | |
AR101555A1 (es) | ANTICUERPOS DIRIGIDOS AL RECEPTOR IIB DE Fc g Y AL RECEPTOR DE Fc e | |
EA201691691A1 (ru) | Белки слияния tatk-cdkl5, их композиции, составы и применение | |
EA202091567A1 (ru) | Химерные белки мти | |
PH12020550099A1 (en) | Fusion protein comprising an fgf-18 moiety | |
EA202191123A1 (ru) | Миниатюризированные дистрофины и их применения | |
BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 |